MARI — Marinomed Biotech AG Balance Sheet
0.000.00%
- €22.05m
- €50.23m
- €9.18m
Annual balance sheet for Marinomed Biotech AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 12 | 9.21 | 5.8 | 8.18 | 2.59 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3.17 | 5.18 | 4.81 | 3.12 | 2.39 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 15.3 | 15.4 | 12.9 | 14.3 | 7.14 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2.49 | 6.04 | 6.43 | 6.2 | 5.94 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 19.5 | 23.5 | 21.3 | 22.3 | 14.6 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.03 | 5.61 | 6.01 | 5.96 | 9.65 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 8.64 | 18.1 | 21.1 | 26.4 | 24.7 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 10.9 | 5.36 | 0.191 | -4.16 | -10.1 |
Total Liabilities & Shareholders' Equity | 19.5 | 23.5 | 21.3 | 22.3 | 14.6 |
Total Common Shares Outstanding |